Table 2. Univariate and multivariate analysis of the prognostic factors for OS in the entire cohort.
| Characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | 0.985 (0.948–1.023) | 0.427 | 0.995 (0.953–1.038) | 0.814 | |
| Gender | |||||
| Male vs. female | 1.614 (0.574–4.537) | 0.364 | 2.359 (0.433–12.842) | 0.321 | |
| Smoking | |||||
| Yes or ever vs. never | 1.176 (0.520–2.657) | 0.697 | 0.700 (0.172–2.846) | 0.619 | |
| ECOG PS score | |||||
| 2–3 vs. 0–1 | 1.038 (0.550–1.958) | 0.909 | 1.139 (0.542–2.393) | 0.730 | |
| Metastatic state | |||||
| Non-oligo vs. oligo | 1.497 (0.822–2.725) | 0.187 | 1.051 (0.522–2.114) | 0.889 | |
| Response | |||||
| PR + CR vs. SD + PD | 0.600 (0.293–1.227) | 0.162 | 0.693 (0.305–1.574) | 0.381 | |
| Thoracic radiotherapy | |||||
| With vs. without | 0.426 (0.220–0.824) | 0.011* | 0.430 (0.201–0.918) | 0.029* | |
*, statistically significant P values. OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; oligo, oligo-metastases; non-oligo, non-oligo metastases; PR, partial response; CR, complete response; SD, stable disease; PD, progressive disease.